Spinal Muscular Atrophy (SMA) Treatment Landscape: SMN-Dependent vs. SMN-Independent Therapeutic Strategies

Spinal Muscular Atrophy (SMA) has long been considered one of the most debilitating genetic neuromuscular diseases, primarily affecting infants and children. However, the emergence of novel therapies over the past decade has transformed SMA from a fatal diagnosis into a treatable condition for many patients. This transformation is the result of two primary therapeutic strategies: SMN-dependent approaches, which aim to restore levels of survival motor neuron (SMN) protein, and SMN-independent approaches, which seek to address the consequences of SMN deficiency through alternative biological mechanisms.

This blog explores these two complementary paradigms in SMA treatment—what they are, how they work, and why their integration could shape the future of SMA care.

The Biology of SMA: A Primer

SMA is caused by a mutation or deletion in the SMN1 gene, responsible for producing the SMN protein necessary for the survival of motor neurons. Without adequate SMN protein, motor neurons degenerate, leading to muscle wasting, loss of mobility, and, in severe cases, respiratory failure.

Humans also possess a second gene, SMN2, which can partially compensate for the defective SMN1. However, due to a splicing error, the majority of SMN2-derived protein is truncated and nonfunctional. The number of SMN2 copies a person has can influence disease severity, with more copies often correlating with a milder phenotype.

SMN-Dependent Therapies: Targeting the Root Cause

SMN-dependent therapies focus on correcting the underlying genetic cause of SMA—insufficient SMN protein—by either enhancing SMN2 function or replacing SMN1. These approaches have revolutionized the field and are the current standard of care.

1. Nusinersen (Spinraza)

Approved in 2016, Spinraza is an antisense oligonucleotide (ASO) administered intrathecally. It modifies SMN2 splicing to promote the inclusion of exon 7, resulting in increased production of full-length SMN protein. Clinical trials have shown that nusinersen significantly improves motor function and survival in both infantile and later-onset SMA patients. The need for repeated lumbar punctures is a limitation, especially in patients with scoliosis or spinal fusion.

2. Onasemnogene Abeparvovec-xioi (Zolgensma)

Zolgensma, a one-time intravenous gene therapy, delivers a functional copy of the SMN1 gene using an adeno-associated virus (AAV9) vector. It was approved in 2019 for children under two years of age. Zolgensma provides systemic expression of SMN protein and has demonstrated life-saving effects when administered early. However, concerns remain about immune reactions, liver toxicity, and long-term durability of gene expression.

3. Risdiplam (Evrysdi)

Risdiplam is an oral small molecule that, like nusinersen, enhances exon 7 inclusion in SMN2 transcripts. Approved in 2020, it is the first at-home oral treatment option for SMA, making it particularly beneficial for patients who cannot easily access hospital-based therapies. It has shown broad efficacy across SMA types and age groups and provides a less invasive treatment alternative.

SMN-Independent Therapies: Addressing the Downstream Effects

While SMN-dependent therapies aim to restore SMN protein levels, SMN-independent strategies focus on compensating for the loss of motor neuron function and improving overall neuromuscular health. These approaches are particularly valuable as adjunct therapies and may benefit patients who do not fully respond to SMN-targeted treatments.

1. Myostatin Inhibitors

Myostatin is a protein that negatively regulates muscle growth. Inhibiting myostatin can enhance muscle mass and strength, potentially counteracting the muscle atrophy seen in SMA. Apitegromab (SRK-015), developed by Scholar Rock, is a monoclonal antibody targeting latent myostatin. Early trials have shown promising improvements in motor function, particularly in patients already on SMN-upregulating therapies.

2. Muscle Activators

Reldesemtiv, a fast skeletal muscle troponin activator, enhances muscle contractility without increasing fatigue. While it doesn't address motor neuron loss, it improves muscle function and endurance, which can enhance quality of life and reduce caregiver burden.

3. Neuroprotective Agents

Agents like olesoxime aim to stabilize mitochondrial function in motor neurons and prevent their degeneration. Though clinical development has been less successful than anticipated, the neuroprotective concept remains a valuable area of research, especially for more advanced-stage patients.

Comparative Advantages and Limitations

Strategy	Mechanism of Action	Strengths	Limitations
Nusinersen	SMN2 splicing modulation (ASO)	Proven efficacy; used across all SMA types	Intrathecal delivery; lifelong administration
Zolgensma	Gene replacement (AAV9 vector)	One-time dose; early intervention is powerful	High cost; limited to young children
Risdiplam	SMN2 splicing modulation (oral)	Convenient dosing; systemic effect	Long-term safety still under evaluation
Apitegromab	Myostatin inhibition (muscle building)	Boosts muscle mass and strength	Adjunctive; does not address neuron loss
Reldesemtiv	Muscle contractility enhancement	Increases endurance	Symptomatic only; clinical impact under study

Toward a Combination Treatment Model

The future of SMA treatment likely lies in a hybrid model that combines SMN-dependent and SMN-independent therapies. This comprehensive approach could provide multiple layers of benefit—restoring SMN protein levels while simultaneously enhancing muscle strength, preventing neuronal loss, and addressing secondary complications like fatigue, scoliosis, and respiratory issues.

Clinical trials exploring such combinations are underway. For example, studies combining risdiplam with apitegromab are investigating synergistic effects on motor outcomes. Personalized medicine—tailoring combinations based on genetic profile, disease severity, and age—will be the next frontier.

Challenges Ahead

Despite these remarkable strides, several hurdles remain:

• Access and Affordability: Zolgensma’s price (~$2.1 million) and the ongoing cost of Spinraza or Risdiplam raise questions about health equity, especially in low-resource settings.

• Early Diagnosis: The effectiveness of SMN-restorative therapies is greatest when administered pre-symptomatically. Thus, universal newborn screening for SMA is critical for timely intervention.

• Long-Term Monitoring: While short-term efficacy is established, long-term durability, especially for gene therapies, remains to be determined. The need for potential re-dosing in the future is unknown.
  

Conclusion

SMA has transitioned from a devastating childhood disorder to a manageable condition, thanks to rapid advancements in both SMN-dependent and SMN-independent treatments. These therapeutic pathways, while distinct, are not mutually exclusive. Together, they represent a powerful arsenal against the multifaceted nature of SMA.

As the treatment landscape continues to evolve, collaborative efforts between clinicians, researchers, biotech companies, and policy-makers will be vital in ensuring that every patient has access to timely, effective, and affordable care.

  Please write to enquire@grgonline.com to learn how GRG Health is helping clients gather more in-depth market-level information on such topics.